Sudeep Pharma (SUDEEPPHRM) Stock Overview
Manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SUDEEPPHRM from our risk checks.
SUDEEPPHRM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read more
Sudeep Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹648.50 |
| 52 Week High | ₹795.00 |
| 52 Week Low | ₹524.05 |
| Beta | 0 |
| 1 Month Change | 15.62% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -16.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| SUDEEPPHRM | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | -4.0% | -2.1% | -0.9% |
| 1Y | n/a | 4.6% | 12.2% |
Return vs Industry: Insufficient data to determine how SUDEEPPHRM performed against the Indian Chemicals industry.
Return vs Market: Insufficient data to determine how SUDEEPPHRM performed against the Indian Market.
Price Volatility
| SUDEEPPHRM volatility | |
|---|---|
| SUDEEPPHRM Average Weekly Movement | 6.5% |
| Chemicals Industry Average Movement | 5.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stable Share Price: SUDEEPPHRM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: Insufficient data to determine SUDEEPPHRM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 480 | Sujit Bhayani | www.sudeeppharma.com |
Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. The company provides mineral salts, such as calcium, zinc, iron, potassium, magnesium, sodium, and copper to a range of health-focused applications; and calcium carbonate, which is used as an active pharmaceutical ingredient for various therapeutic applications. It also offers micronutrient premixes, encapsulated ingredients, liposomal and spray-dried formats, granulated minerals, and triturated blends to meet the needs across functional foods, dietary supplements, infant and clinical nutrition, fast-moving consumer goods, and convenience food formulations.
Sudeep Pharma Limited Fundamentals Summary
| SUDEEPPHRM fundamental statistics | |
|---|---|
| Market cap | ₹73.25b |
| Earnings (TTM) | ₹1.68b |
| Revenue (TTM) | ₹6.17b |
Is SUDEEPPHRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUDEEPPHRM income statement (TTM) | |
|---|---|
| Revenue | ₹6.17b |
| Cost of Revenue | ₹2.26b |
| Gross Profit | ₹3.91b |
| Other Expenses | ₹2.23b |
| Earnings | ₹1.68b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.89 |
| Gross Margin | 63.38% |
| Net Profit Margin | 27.24% |
| Debt/Equity Ratio | 19.3% |
How did SUDEEPPHRM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/25 02:42 |
| End of Day Share Price | 2026/02/25 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sudeep Pharma Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sanjesh Jain | ICICI Securities Ltd. |